In this multicenter retrospective study, the long-term outcomes of 878 adults with AML and refractory anemia with excess blasts (RAEB) with BM blasts o10% who underwent transplantation with an HLA-identical sibling donor between 1998 and 2004 were analyzed according to four regimens of conditioning intensity: reduced-intensity conditioning (RIC) (either intermediate RIC (IntermRIC) or non-myeloablative (NMA) RIC), and myeloablative conditioning (MC) in 718 patients (either conventional MC or hyperintense MC. In multivariate cox analysis, patients undergoing NMA transplantation had lower non-relapse mortality risk in the first 100 days after transplantation (Po0.01), but a higher risk beyond day þ 100 (P ¼ 0.02), as well as higher relapse incidence in the first 12 months (Po0.01), but the risk was similar in all groups beyond 12 months. The probabilities of PFS and OS up to 7 years were significantly lower only in the NMA subgroup (Pp0.01 for both). The 7-year OS was 53%, 29%, 56% and 51%, respectively. Our data suggest that prospective studies comparing RIC regimens (especially IntermRIC) with MC are appropriate in patients with AML and RAEB who are in a non-advanced disease status.
INTRODUCTION
Allogeneic hematopoietic SCT (AlloHSCT) can allow for long-term disease-free survival in patients with high-risk AML or myelodysplasia (MDS), with 5-year survival ranging from 40-50%.
1-3 Many patients with AML or high-risk MDS are not considered candidates for conventional myeloablative conditioning (MC) procedures because of advanced age, previous therapies or comorbidities. Reduced-intensity conditioning (RIC) regimens were developed in the late 1990s to reduce the early non-relapse mortality (NRM) with MC and allow patients ineligible for these procedures to benefit from a putative GVL effect. 4, 5 A wide variety of MC and RIC regimens have been described in AML and MDS, ranging from intensified MC to minimal-intensity RIC regimens (referred to as non-myeloablative (NMA) regimens). [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] Current data suggest that RIC regimens can reduce the early morbidity and NRM, but at the expense of higher risk of disease relapse in MDS and AML. Most of the available studies, however, include very heterogeneous patient populations, including the intensity of the conditioning regimen, with a short follow-up, 8, 9, [19] [20] [21] and longer follow-up is clearly needed to better interpret the impact of the intensity of the conditioning regimen on transplantation outcomes.
Thus, in order to better address the important question of whether the intensity of the preparative regimens used for AML/ MDS in an early/intermediate status at transplantation has an impact on long-term survival and on other key outcomes, we performed a retrospective, multicenter study which included only patients transplanted before 2005 who received an HLA-identical sibling HSCT.
PATIENTS AND METHODS

Inclusion criteria and definitions
Data were provided by the Acute Leukemia and chronic Malignancies Working Parties of the European Group for Blood and Marrow Transplantation (EBMT) group. EBMT is a voluntary working group of more than 500 transplant centers, participants of which are required once a year to report all consecutive SCTs and follow-up. The Acute Leukemia and chronic malignancies Working Parties of the EBMT group approved this study that was conducted according to the principles of the declaration of Helsinki.
Patient details are shown in Table 1 . In the study, 878 patients from 46 centers who agreed to participate were included. Patients had to have a diagnosis of AML (de novo, secondary and therapy-related cases, as well as the formerly-defined refractory anemia with excess blasts in transformation) or RAEB types 1 and 2 in an early/intermediate status at transplantation. Furthermore, patients had to be in first or second CR or PR, after no more than 2 lines of disease-directed therapy and with o10% BM blasts at the time of transplantation (thus, the study excluded those in advanced disease status). Early disease status included AML, RAEB-2 in first CR and untreated RAEB-1, while intermediate disease status included any CR beyond first and any PR. Only first AlloHSCT from an HLA-identical sibling HSCT performed between January 1998 and December 2004 were included in this analysis. In addition, all participating centers completed for all their consecutive patients a study-designed case report form (MED-C), which included missing detailed information on all relevant HSCT-related variables and outcomes.
The intensity or type of conditioning regimen was defined by established criteria. 6, 7, 19 Conditioning regimens considered in the current study are described in Table 2 . The most common MC included CY plus high-dose TBI (X8 Gy fractionated or X5 Gy single dose) (CY-TBI) or CY plus high-dose BU (48 mg/kg total oral dose or the equivalent i.v. dose) (Bu-CY), with or without other high-dose cytotoxic agents and/or antithymocyte globulin or alemtuzumab. MC were subclassified into two categories: (i) Conventional MC (ConvMC); and (ii) Hyperintensive MC (HyperMC), in case other cytotoxic agents (high-dose melphalan, thiotepa, etoposide or Ara-C) were added to the ConvMC.
RIC regimens were also subclassified into two categories, as previously suggested: 6, 7 (iii) Intermediate-intensity RIC regimens (IntermRIC), which mostly included fludarabine plus intermediate doses of one or two alkylating agents (BU (p8 mg/kg orally or equivalent i.v. dose), i.v. melphalan (80-140 mg/m 2 total dose), i.v. CY (120 mg/kg), i.v. thiotepa (5-10 mg/kg) or i.v. treosulfan (30-42 g/m 2 )); and (iv) Minimal-intensity RIC (hereafter referred to as NMA), which included fludarabine plus low-dose TBI (2 Gy) or low-dose BU (4 mg/kg orally or equivalent i.v. dose), with or without antithymocyte globulin or alemtuzumab. Owing to the retrospective nature of the study, the reason(s) for inclusion in a RIC protocol and exclusion from a MC in each transplantation group were not available Unfavorable cytogenetics were defined according to established criteria for AML 22, 23 and MDS 24 and included: del(5q)/ À 5, À 7/del(7q), abnormality 3q, 9q, 11q, 17p, t(6;9), t(9;22) and complex cytogenetics (X3 unrelated abnormalities). The EBMT risk score was calculated for each Conditioning intensity in AML/MDS R Martino et al patient as previously published. 25 In the EBMT database, acute and chronic GVHD (aGVHD and cGVHD, respectively) are graded using established criteria. 26, 27 End point definitions Study end points were assessed on the date of last patient contact, and the final database was locked in December 2010. As the median follow-up exceeded 6 years in both cohorts, transplantation outcomes were analyzed up to 7 years after transplantation.
Analysis focused on hematopoietic recovery, aGVHD and cGVHD, NRM, disease relapse or progression, PFS, and OS. The date of neutrophil recovery was defined as the first of 3 consecutive days with an ANC higher than 0.5 Â 10 9 /L, while the date of platelet recovery was defined as the first of 7 consecutive days with a platelet count higher than 50 Â 10 9 /L. Analysis of cGVHD included patients who had neutrophil recovery and survived without disease progression for 490 days after transplantation; cases were coded as absent, limited or extensive.
Statistical methods
The probabilities of PFS and OS were estimated using the Kaplan-Meier method. Starting time for all patients was time of transplantation. Univariate comparisons of outcomes between groups were performed by using the two-tailed log-rank test. The hematopoietic recovery and occurrence of acute and chronic GVHD were calculated using cumulative incidence estimates, taking into account the competing risks structure. 28 NRM and disease relapse or progression were also analyzed with cumulative incidence; for NRM the competing event was relapse, while for relapse the competing event was NRM. Equality of cumulative incidence curves of different groups has been tested by applying a log-rank type test developed by Gray. 29 The variables analyzed are shown in the footnotes of Table 5 .
Multivariate Cox regression modeling was performed to evaluate the predictive effect of the relevant parameters on OS, PFS, relapse incidence and NRM. Competing risks outcomes were modeled by means of causespecific hazards. For multivariate analyses, covariates found to be significant at the 0.10 level or below in the univariate analysis of the outcome of interest were entered into the Cox proportional hazards model for this outcome in a stepwise backward elimination with a criterion of Po0.05 for retention to select a final model. As the primary issue of the current study was to describe the overall impact of the intensity of the conditioning regimen (or 'Type of conditioning regimen') on transplantation outcomes, this variable was held in the models at each step. The EBMT risk index was not included in the analysis as its components were all analyzed separately (patient age, disease status, time interval from diagnosis to transplant, donor type and donor-recipient sex combination). Grades III-IV aGVHD and cGVHD were introduced in the final models for NRM, relapse, PFS and OS as time-dependent covariates. Departure from the proportional hazards assumption was assessed by including a timedependent covariate for each factor. In case of violation of the proportional hazards assumption for a specific covariate (different effects over time), models were constructed by breaking the period after transplantation into two time periods. Maximum likelihood methods were employed to find the most appropriate break point. Eventually the final multivariate model was built by considering the time-varying effects of a specific covariate. For NRM and relapse the variable intensity of the conditioning regimen (main study variable) had a time-varying effect that violated the proportionality assumption. The method described above was employed to find the most appropriate break point of the post transplant period, which was day þ 100 for NRM and þ 12 months for relapse (see details in the section Results); using these cut points, the proportionality assumption held for both NRM and relapse, respectively.
When groups were compared according to continuous covariates, the Mann-Whitney U-test or Kruskal-Wallis 1-way analysis of variance on ranks test were used for differences in medians. According to the group sizes, a w 2 analysis or Fisher's exact test was used to compare categorical covariates. SPSS version 18 (SPSS, Chicago, IL, USA) was used for all statistical analyses, except for the competing risks analysis, which was performed by using NCSS 2010 (Number Cruncher Statistical System, Kaysville, UT, USA) software.
All the analyses described were first executed in the entire potential patient cohort from the EBMT database (n ¼ 3053 cases with AML and RAEB registered as being in an early/intermediate disease status), and then in the 878 patients from the centers who accepted to participate in the study by providing all the extensive extra study variables from all the consecutive patients in their center who met the inclusion criteria. This separate analysis was intended to identify whether the 'missing' group of potential patients from non-participating institutions had any different outcomes that would suggest a selection bias. As the results from the entire EBMT database group did not differ from the 878 study patients in the probability of OS and PFS, or in the incidence of relapse and NRM (details not shown), a relevant selection bias could be excluded.
RESULTS
Patient and transplant characteristics
As expected, baseline patient characteristics differed between the two study groups. Table 1 shows patient, disease and transplant characteristics of the 878 transplant recipients. MC recipients were younger than those in the RIC groups (Po0.001), and a low EBMT risk score was more common in the MC (36%) than in the RIC groups (6%) [Po0.01], as was the proportion of patients transplanted in early disease phase (84 vs 78%, P ¼ 0.04). Table 2 provides details concerning the conditioning regimens used and the GVHD prophylaxis.
Hematopoietic recovery and GVHD The details of hematopoietic recovery and GVHD are shown in Table 3 . The cumulative incidence of grade I-IV acute aGVHD by day þ 120 was higher in the MC groups than in the RIC groups, and its onset was earlier in the former. The 7-year incidence of cGVHD did not differ between the transplant groups. There were Other ¼ high-dose etoposide, high-dose Ara-C, high-dose thiotepa, high-dose melphalan or idarubicin.
Conditioning intensity in AML/MDS R Martino et al no differences in hematopoietic recovery, aGVHD or cGVHD between the HyperMC and ConvMC subgroups, or between the IntermRIC and NMA subgroups (data not shown).
Non-relapse mortality In univariate analysis, the cumulative incidence for NRM up to 7 years was 23% (95% confidence interval (CI), 20-26%) and 19% (95% CI, 14-28%) in patients undergoing MC and RIC transplantation, respectively (P ¼ 0.2 by Gray's test). In patients older than 50 years, the 7-year NRM was 41% in 104 MC recipients and 21% in 120 RIC recipients (Po0.01, data not shown). Table 3 shows the 7-year incidence of NRM, with no statistically significant difference found in the 7-year NRM between the four conditioning intensity subgroups. Table 4 shows the univariate and multivariate analyses for NRM and relapse. In multivariate analysis, patients who received NMA conditioning had a lower hazard ratio (HR) of NRM in the first 100 days after transplantation (HR 0.21, Po0.01). The 100-day NRM was 22%, 11%, 4% and 0% in the HyperMC, ConvMC, IntermRIC and NMA subgroups, respectively (Figure 1a) . However, beyond day þ 100 (up to þ 7 years) NMA recipients had a higher 
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HR of NRM (HR 2.4, P ¼ 0.02). The landmark þ 100-day to þ 7-year cumulative incidence of NRM in the conditioning groups is shown in Figure 1b . Other variables with a negative impact on NRM in multivariate analysis are shown in Table 4 .
Relapse
In univariate analysis, the cumulative incidence of relapse up to 7 years was 23% (95% CI, 20-27%) and 39% (95% CI, 32-48%) in patients undergoing MC and RIC transplantation, respectively (P ¼ 0.01). There was a statistically significant difference in the 7-year relapse between the four conditioning intensity subgroups, as shown in Table 3 .
In Table 4 , univariate and multivariate analyses for relapse are shown. In multivariate analysis, patients who received NMA conditioning had a higher relapse risk in the first 12 months after transplantation (HR 3.9, Po0.01 Table 4 ). The 12-month relapse was 13%, 15%, 22% and 41% in the HyperMC, ConvMC, IntermRIC and NMA subgroups, respectively (see Figure 2) . However, between 12 months and 7 years the risk of relapse did not differ among the conditioning intensity groups (P ¼ 0.3). Other variables with a negative impact on relapse in multivariate analysis are shown in Table 4 .
Survival
In univariate analysis, the 7-year PFS was 54% (95% CI, 50-58%) and 42% (95% CI, 34-50%) in patients undergoing MC and RIC transplantation, respectively (P ¼ 0.03), while the 7-year OS was 56% (95% CI, 52-59%) and 48% (95% CI, 40-56%), respectively (P ¼ 0.2). There was a statistically significant difference in the 7-year PFS and OS between the four conditioning intensity Conditioning intensity in AML/MDS R Martino et al subgroups, as shown in Table 3 and Figure 3 (univariate Po0.01 for both). Table 5 shows the results of the univariate and multivariate analyses of PFS and OS. In multivariate analysis NMA led to a lower PFS (HR 1.9, 95% CI 1.2-3) and a lower OS (HR 1.9, 95% CI 1.1-3.1), while other variables that were found to have a negative impact on PFS are shown in Table 5 .
We also analyzed the impact of the intensity of the conditioning regimen on the OS in different EBMT risk categories. 25 The possible EBMT risk scores ranged from 0 to 5 points. The 7-year OS in the MC and RIC groups for the low-risk category (0-1 point) was 61% and 60%, respectively (P ¼ 0.9); in the intermediate-risk category (2-3 points) 54% and 48%, respectively (P ¼ 0.3); and in the high-risk category (4-5 points) 35% and 49%, respectively (P ¼ 0.06).
Outcomes in patients with age above 50 years As shown in Table 1 , 224 patents were older than 50 years (14 in the HyperMC, 90 ConvMC, 90 IntermRIC and 30 in the NMA conditioning categories).The 7-year NRM in these patients was 51%, 41%, 24% and 31%, respectively (Po0.01 for the comparison of IntermRIC þ NMA vs both the MC groups), while the relapse was 28%, 22%, 29% and 49%, respectively (P ¼ 0.2). The 7-year OS was 21%, 41%, 56% and 27%, respectively (Po0.01 for the comparison of IntermRIC vs other groups).
DISCUSSION
The key finding of the current study is that the short and long-term outcomes are influenced by the conditioning regimen intensity, and especially, long-term outcomes may differ within subtypes of the formerly referred to as 'RIC regimens' (IntermRIC and NMA regimens). Unfortunately, the NMA category included only 34 cases, and thus our findings could be due to chance alone and further studies are required. Nevertheless, this observation is in line with other large registry studies. Prior studies from the EBMT ALWP 12, 19 and the Chronic Leukemia Working Party (CLWP) 17 compared the outcomes of AlloHSCT from HLA-identical siblings in AML and MDS, but all disease stages were included, the follow-up was short, and the conditioning regimens were classified simply as either MC or RIC. A later study by Gorin et al. 30 on behalf of the ALWP showed that the 17-month relapse incidence was higher with NMA conditioning, while the NRM did not differ. Luger et al. 9 recently published a study on behalf of the Center for International Blood and Marrow Transplant Research, which included AML and MDS in all disease status and donor types, with a median follow-up of 3-5 years. In multivariate analysis, only NMA regimens resulted in significantly worse 5-year relapse, PFS and OS.
In another recently published retrospective study from the Center for International Blood and Marrow Transplant Research, McClune et al. 13 analyzed the outcomes in patients older than age 40 years with AML or MDS in an early disease status who received a RIC (either IntermRIC or NMA) and found a higher relapse risk at 2 years in patients receiving NMA conditioning compared with IntermRIC (HR ¼ 1.46; P ¼ 0.002), whereas NMA regimens were associated with a borderline lower risk of 1-year NRM, but not at 2 years post transplant.
The only prospective randomized trial available to date was recently reported in abstract form by Bornhauser et al. 31 In this trial, 195 young adults with AML in first CR eligible for MC were randomized to receive a MC regimen with CY-TBI (1200 cGy) or an IntermRIC regimen consisting of fludarabine and TBI (800 cGy), which was chosen following the good results obtained in a prior phase 2 study. 32 The primary end point (NRM after 12 months) was lower in the IntermRIC (8%) than in the MC group (17%) (Po0.05), especially in patients 440 years of age (5 vs 20%, P ¼ 0.01). In addition, the incidence of relapse did not differ. The results from our study are in concordance with the preliminary findings from this trial, showing that in patients with AML in an Conditioning intensity in AML/MDSearly disease status, an IntermRIC regimen can result in significantly lower early NRM without increasing the relapse risk. The 3-year outcomes of the IntermRIC regimens in the current study are in line with those found in prior studies (after excluding patients in an advanced disease status). 4, 16, 19, [32] [33] [34] [35] In addition, long-term follow-up of the most common NMA protocol (Fludarabine þ 200 cGy TBI 36 ) in patients with AML in first or second CR reported a 6-year relapse incidence of 62%, a 27% PFS and an OS of 29%, similar to our cohort of NMA recipients. 37 Long-term comparative outcomes of various conditioning regimen intensities for AlloHSCT in AML and poor-risk MDS are not available to date. As opposed to prior studies, our study population was relatively homogeneous. In addition, we required a lot of extra data from the participating centers, and, as a result, the sample size for the NMA category was small. With this caveat in mind, the results of the multivariate analysis clearly found worse outcomes only for this subgroup of RIC regimens, while the IntermRIC had nearly identical short and long-term outcomes to the MC cohorts. Although early NRM was less with RIC approaches, the data indicate that the increased risk of late NRM (beyond day þ 100) negated any early advantage offered by NMA regimens, resulting in lower 7-year PFS and OS in recipients of NMA conditioning. Age 450 years, poor-risk cytogenetics, poor performance status, any method of T-cell depletion (negative impact on PFS only), severe aGVHD and not developing cGVHD had a deleterious impact on 7-year PFS and OS.
The impact of GVHD on long-term outcomes in the current study is of special interest. GVHD can induce NRM but can also augment the GVL effect after AlloHSCT. Severe aGVHD (grade III-IV) increased the NRM and reduced PFS and OS in the current study, as expected, 38 while chronic GVHD, on the other hand, reduced the relapse without increasing the NRM, thus improving the 7-year PFS and OS. The cGVHD-associated GVL effect was important in limiting leukemia recurrence both early (first year) Conditioning intensity in AML/MDSand late (after the first year post-HSCT), as the HR remained equal throughout the 7-year period. On the other hand, the use of T-cell depletion increased the relapse risk, as recently reported in a large Center for International Blood and Marrow Transplant Research study on recipients of IntermRIC. 39 As with all retrospective registry studies, numerous biases may affect our analysis. Although the exact reason(s) for the choice of preparative regimens are not known, elderly age and comorbidities were surely the main reasons for using a RIC approach. Compared with the MC groups, the RIC groups were older, had a poorer performance status and had higher EBMT risk scores at transplant, and one can assume that most patients who received an IntermRIC or NMA regimen would not have been candidates for MC transplants. On the other hand, the lack of detailed comorbidity data prevents us from examining to what extent these important patient-related variables had a role in the decision of the intensity of the regimen used. However, these data suggest that IntermRIC regimens yield long-term survival similar to MC regimens in patients with non-advanced AML/MDS. On the other hand, NMA conditioning may be associated with more early relapses and late NRM, leading to an inferior PFS and OS compared with the other levels of regimen intensities. However, as our study included only 34 cases of NMA conditioning, the results could be due to chance alone and thus further detailed comparisons in large patient cohorts are required.
